旨在研究 [18F]FDG 全身 (WB) 正电子发射断层扫描 - 磁共振 (PET-MR) 组合的可行性研究，包括在单一方案中集成乳腺 MR，用于乳腺癌患者的局部和远处分期。前瞻性地纳入了根据传统成像方式（全视野数字乳房X线摄影（FFDM）和超声（US））连续诊断的乳腺癌患者。所有患者均接受了 [18F]FDG WB PET-MR，包括综合专用乳腺 MR（俯卧位）和 WB PET-MR（仰卧位）方案。将 [18F]FDG WB PET-MR（包括整合乳腺 MR）的结果与传统成像方式进行比较。从 2021 年 4 月至 2022 年 4 月，纳入了 28 名患者。常规影像学显示，28 名患者中有 22 名（FFDM）和 23 名（美国）患有 cT1-2 乳腺癌。关于临床淋巴结状态，8名患者被认为是cN0，18名患者被认为是cN1（1-3个可疑淋巴结），2名患者被认为是cN2（4个可疑腋窝淋巴结/内乳淋巴结转移）。 [18F]FDG WB PET-MR，包括综合乳腺 MR 方案，根据 [18F]FDG WB PET-MR 和乳腺 MR 结果，对两名患者的临床肿瘤状态和九名患者的临床淋巴结状态进行了升期。此外，在三名患者（肝脏/骨）中检测到远处转移，另一名患者被诊断患有同步原发性肿瘤（肺癌）。[18F]FDG WB PET-MR，包括在单一方案中集成乳腺 MR乳腺癌患者的研究是可行的，并且为乳腺癌患者的局部和远处分期提供了一种有前景的新方法。关键相关性声明：[18F]FDG 全身 PET-MR，包括集成的乳腺 MR 方案，是可行的，并且允许在乳腺癌患者的单次影像检查中进行局部和远处分期。[18F]FDG PET-MR 允许组合乳房 MR 和全身分期。因此，研究了全身 [18F]FDG PET-MR 的单一方案，包括集成乳腺 MRI。 [18F]FDG PET-MR，包括综合乳腺 MR 是可行的，可以在日常临床实践中考虑。© 2024。作者。

To investigate in a feasibility study the combination of [18F]FDG whole-body (WB) positron emission tomography-magnetic resonance (PET-MR), including an integrated breast MR within a single protocol for locoregional and distant staging in breast cancer patients.Consecutive patients with breast cancer diagnoses according to conventional imaging modalities (full-field digital mammography (FFDM) and ultrasound (US)) were prospectively included. All patients underwent [18F]FDG WB PET-MR, including an integrated dedicated breast MR (prone position) and WB PET-MR (supine position) protocol. Results of [18F]FDG WB PET-MR, including integrated breast MR, versus conventional imaging modalities were compared.From April 2021-April 2022, 28 patients were included. On conventional imaging, cT1-2 breast cancer was present in 22 (FFDM) and 23 (US) out of 28 patients. With regard to clinical nodal status, eight patients were considered cN0, eighteen cN1 (1-3 suspicious lymph nodes), and two patients were cN2 (four suspicious axillary lymph nodes/internal mammary lymph node metastasis). [18F]FDG WB PET-MR, including an integrated breast MR protocol, upstaged clinical tumor status in two patients and clinical nodal status in nine patients according to both [18F]FDG WB PET-MR and breast MR findings. In addition, distant metastases were detected in three patients (liver/bone), and another patient was diagnosed with a synchronous primary tumor (lung cancer).[18F]FDG WB PET-MR, including an integrated breast MR within a single protocol in breast cancer patients, is feasible and provides a promising new approach in breast cancer patients with regard to locoregional and distant staging. CRITICAL RELEVANCE STATEMENT: [18F]FDG whole-body PET-MR, including an integrated breast MR protocol, is feasible and allows locoregional and distant staging within a single imaging exam in breast cancer patients.[18F]FDG PET-MR allows the combination of breast MR and whole-body staging. Therefore, a single protocol of whole-body [18F]FDG PET-MR, including an integrated breast MRI, is investigated. [18F]FDG PET-MR, including an integrated breast MR is feasible and can be considered in daily clinical practice.© 2024. The Author(s).